key: cord-0967835-neb0gfp6
authors: Souverbielle, Cristina Tomatis; Wang, Huanyu; Feister, John; Campbell, Jason; Medoro, Alexandra; Mejias, Asuncion; Ramilo, Octavio; Pietropaolo, Domenico; Salamon, Douglas; Leber, Amy; Erdem, Guliz
title: Year-round, Routine Testing of Multiple Body Site Specimens for Human Parechovirus in Young Febrile Infants
date: 2020-10-09
journal: J Pediatr
DOI: 10.1016/j.jpeds.2020.10.004
sha: ebb18131b36eedb581f688bf8694c4c5a5ceed33
doc_id: 967835
cord_uid: neb0gfp6

OBJECTIVES: To test our hypothesis that routine year-round testing of specimens from multiple body sites and genotyping of detected virus would describe seasonal changes, increase diagnostic yield and provide a better definition of clinical manifestations of human parechovirus (PeV-A) infections in young febrile infants. STUDY DESIGN: PeV-A reverse transcriptase-PCR was incorporated in routine evaluation of infants ≤60 days hospitalized at Nationwide Children’s Hospital for fever and/or suspected sepsis-like syndrome beginning in July 2013. We reviewed electronic medical records of infants who tested positive for PeV-A from July 2013 to September 2016. Genotyping was performed with specific type 3 RT-PCR and sequencing. RESULTS: Of 1475 infants evaluated, 130 (9%) tested positive for PeV-A in one or more sites: 100 (77%) in blood, 84 (65%) in a non-sterile site, and 53 (41%) in cerebrospinal fluid (CSF). Five (4%) infants had CSF only positive, 31 (24%) blood only, and 20 (15%) non-sterile site only positive. PeV-A3 was the most common type (85%) and the only type detected in CSF. Although the majority (79%) of infections were diagnosed between July and December, PeV-A was detected year-round. Median age was 29 days. Fever (96%), fussiness (75%) and lymphopenia (56%) were common. Among infants with PeV-A positive CSF, 77% had no CSF pleocytosis. Median duration of hospitalization was 41 hours. Four infants had bacterial coinfections diagnosed within 24 hours of admission; 40 infants had viral coinfections. CONCLUSIONS: While most frequent in summer and fall, PeV-A infections were encountered in every calendar month within the 3-year period of study. More than one-half of patients had PeV-A detected at more than one body site. Coinfections were common. PeV-A3 was the most common type identified, and the only type detected in the CSF.

Human parechoviruses (PeV-A) are non-enveloped RNA viruses previously classified as enteroviruses 1, 2 . PeV-A infections are associated with fever, sepsis and meningitis in young infants 1, 2 . Of 19 PeV-A types, types 1 and 3 commonly cause illnesses in young infants [2] [3] [4] [5] [6] [7] , PeV-A3 has been associated with ICU admission, seizures, death, and poor neurodevelopmental outcomes 5, 8 . Clinical manifestations of other PeV-A types are not well defined 4, 9, 10 .

PeV-A infections peak during summer and fall months but seasonality and overall epidemiology are incompletely understood 2, 3, 9, [11] [12] [13] [14] . It has been reported that testing blood in addition to CSF increases PeV-A detection 15, 16 but this has not been widely implemented.

Combining PeV-A PCR with enterovirus (EV) PCR, thus testing for both viruses at the same time has been described as helpful 16, 17 . At our institution, in addition to routine herpes virus and enterovirus polymerase chain reaction (PCR) testing, reverse-transcriptase PCR (RT-PCR) testing for PeV-A of blood, CSF and non-sterile sites has been included in the standard evaluation of young infants (≤60 days) presenting with fever and possible sepsis since July 2013.

The objectives of this study were to define the year-round epidemiology, the clinical and laboratory findings associated with PeV-A infections in infants ≤60 days, and when possible, to identify virus types associated with disease severity. We hypothesized that performing routine testing of specimens from multiple body sites at the time of initial encounter and genotyping PeV-A detected will improve understanding of clinical disease.

J o u r n a l P r e -p r o o f METHODS Electronic medical records of infants ≤60 days hospitalized between July/2013 and September/2016 for fever and/or possible sepsis and tested for PeV-A were identified. Of these, infants who had positive PeV-A RT-PCR from any clinical sample were included. All infants had bacterial cultures obtained. Laboratory records were accessed to determine if samples were available for further testing.

In order to define seasonality, clinical and laboratory findings we collected demographic and seasonal information including date, age, gestational age and sex, presenting symptoms and signs [e.g., fever, rash, seizures, fussiness/irritability, diarrhea, cough, congestion], complete blood count and differential of white blood cells, blood chemistry, imaging, additional viral testing for enterovirus, HSV, and respiratory viruses, bacterial cultures from blood, urine and cerebrospinal fluid (CSF), ) antibiotic treatment and duration, types of samples that tested positive for PeV-A RT-PCR (CSF, blood, and non-sterile specimens from throat, rectum, skin, mouth, conjunctival swabs or "pooled specimens" which combined any of the previous sites) and semi-quantitative PeV-A loads, and clinical outcomes including admission to pediatric intensive care unit (PICU), duration of hospitalization, and readmission within seven days due to same illness. During the study years, two different respiratory viral panel PCR assays were in use: single-plex PCR assays that detect six respiratory viruses (respiratory syncytial virus [ J o u r n a l P r e -p r o o f

PeV-A was detected using a real time RT-PCR assay as previously described by Nix et al 18 . Semi-quantitation of viral loads were analyzed and reported as cycle threshold (Ct) values, which represented the number of cycles required to detect a positive result.

We first screened available samples for PeV-A3 using a PeV-A3-specific RT-PCR assay as described 19 . The samples with adequate RNA quantity and quality that tested negative for PeV-A3 were sequenced for the partial viral protein 1 (VP1) region 20 . Sequence assembly was performed using Geneious software (www.geneious.com). Partial VP1 sequences were blasted and genotypes were assigned as per Genbank.

We report continuous variables as mean ± SD, or as medians, 25%-75% interquartile range (IQR) and analyzed using t-test or non-parametric tests according to data distribution. We analyzed categorical data by Fisher exact test, and computed correlations using Spearman r test for non-normally distributed data. A P value of < .05 was considered statistically significant. Analyses were made using GraphPad Prism version 7.03 (GraphPad Software, La Jolla CA).

Between July/2013 and September/2016, 1475 infants <60 days were tested for PeV-A by RT-PCR. Patients predominantly came to medical attention because of fever and were well appearing or had a sepsis-like picture, respiratory distress or concern for meningitis/CNS disease. 

We analyzed the 20 infants who had only a non-sterile site positive for PeV-A separately, and the only significant differences were that these infants had a higher proportion of respiratory symptoms (65% vs 20%, p<0.01) and were fussy less frequently (40% vs 75%, p<0.01).

During the study period, 103 (79%) of positive PeV-A infants presented between July-December. However, from 2013 through 2015, most diagnoses were made between August-October, while in 2016, patients were identified as early as May with a peak in July (Figure 2) . During the study period, enterovirus infections were twice as common (289/1475, 20%).

Forty-four (34%) patients with PeV-A detection had another agent identified by culture or by PCR. Forty infants (25 with PeV-A in CSF or blood; 15 from non-sterile sites) had viral co-detection. Two infants had bacteremia, two had urinary tract infections (UTI). Coinfections Four infants had serious bacterial infections; all bacterial cultures were positive within 24 hours of incubation. The first infant was a 28-day, full-term male evaluated for fever whose blood culture was positive for Streptococcus pneumoniae at approximately 24 hours after inoculation. His CSF studies were normal and CSF culture was sterile. His CSF was positive for PeV-A. A blood culture repeated before antibiotic therapy was sterile.

The second infant was a 33 day old, full-term male, with history of gastroesophageal reflux and tracheomalacia. He presented with respiratory distress, fever and fussiness and was treated with ampicillin/sulbactam for possible aspiration pneumonia. Blood culture was positive at 14 hours of incubation for group B streptococcus (GBS). His CSF culture was negative; only a pooled non-sterile specimen tested positive for PeV-A.

The third infant was a 13 day-old, full-term female. She was febrile and fussy and urine culture grew E. coli [>100,000 colony-forming units (CFU)/mL] within 16 hours of incubation.

Her CSF sample was obtained on day 9 of hospitalization after several attempts and while receiving IV antibiotics. The CSF had a glucose level of 35 mg/dL, protein 74 mg/dL; 536 RBC/µL and 160 WBC/ µL (with 2% neutrophils and 98% lymphocytes). CSF and blood cultures were negative. She was treated for presumed E. coli meningitis for 21 days. PeV-A virus was detected from an eye swab and coronavirus was detected from a nasopharyngeal swab.

The fourth infant was a 42 day-old, full-term female who had an E.coli UTI identified within 16 hours of urine culture. All samples (CSF, blood, non-sterile sites) tested positive for PeV-A. CSF glucose was 49mg/dL, protein 328 mg/dL; there were >6000 RBC/µL and 31 WBC/ µL.

Overall the semi-quantitative PeV-A loads expressed as medians and IQR of C t values were lower (reflecting higher viral loads) in the blood (31.47 [27.7-34.76 

Of the 130 infants with PeV-A infection, 100 (77%) had samples available for genotyping ( Table 2 ; available at www.jpeds.com) and of these, 87 were PeV-A3. The remaining thirteen infants' genotypes included: PeV-A1 (5), PeV-A4 (6), PeV-A5 (1) and PeV-A6 (1). As the non-PeV-A3 samples were a small portion of the samples tested and did not allow detailed comparison, type comparisons were done between PeV-A3 and non-PeV-A3 types ( Table 3) .

All CSF positive samples (n=36) and the majority of blood samples were PeV-A3. Only three infants had PeV-A4 detected in blood. Genotypes 1, 5 and 6 were detected at non-sterile sites. Of the five infants admitted to PICU with available samples, four had PeV-A3 (4 CSF, 3 blood and 2 from non-sterile sites). One infant requiring PICU care presented with respiratory distress and had concomitant detection of rhinovirus/enterovirus in a respiratory sample and PeV-A1 detected from a non-sterile site.

PeV-A3 was detected year-round, whereas other PeV-A types were identified only during the second half of the year.

Among infants with samples available for genotyping, 26 had viral and two had bacterial co-infections. The infant with GBS bacteremia had PeV-A type 6 identified from a non-sterile specimen and one of the infants with E. coli UTI had PeV-A type 3 detected in CSF, blood and from a nasopharyngeal swab.

This retrospective study describes the routine, year-round application of RT-PCR testing of specimens from multiple body sites for detection of PeV-A infections in young infants hospitalized for fever and/or sepsis-like clinical picture. We showed that PeV-A infections were detected year-round, peaked during late summer-early fall and did not have a striking biennial pattern. In addition to fever and fussiness/irritability, infants commonly had rash, upper respiratory tract symptoms, diarrhea, and abdominal distention. Almost one-half of infants had leukopenia and lymphopenia, 18% had elevated transaminases, and a minority (7%) were admitted to PICU. Co-infections were common (34%) and in several infants were possibly the cause of clinical symptomatology. Some patients with viral co-infections had manifestations more consistent with a respiratory virus. For infants without identified concurrent infections, routine testing was helpful not only to determine the etiology of fever but possibly to avoid unnecessary antimicrobial treatment and shorten hospital stay. Most of PeV-A testing has been performed during summer, thus precise annual distribution or seasonality has not been established and viral circulation during other times of the year may be under-recognized 3, 9, 11, 14 . Data from our cohort demonstrate that PeV-A can be detected year-round and, therefore, testing should be considered throughout the year 11 . PeV testing varies among centers, certain centers test only one compartment, such as CSF 23, 24 or blood or respiratory samples 8, 9, 15, 16, 25 . In our cohort only 24% of PeV-A positive patients were diagnosed due to PeV-A detection in blood and only 15% by detection in a non-sterile site. By testing samples from multiple compartments the diagnostic yield was increased.

PeV-A surveillance and typing data could aid in determining patterns of circulation, spectrum of disease [26] [27] [28] , and potentially prognosis for individual genotypes 3, 29 . Similar to other studies, PeV type 3 was the most common circulating type during our study years 8, 10, 30, 31 . In 2015, Renaud and Harrison 10 showed that PeV type 3 causes seasonal outbreaks and that CNS disease and infections are associated with lack of CSF pleocytosis and leukopenia/lymphopenia Coinfections in patients with PeV-A have not been well studied 28, [35] [36] [37] . We detected coinfections in about one third of our patients and in some infants these other pathogens were possibly the cause of clinical symptomatology. All bacterial infections in our cohort were identified within 24 hours of hospitalization, and there was no interruption of antibiotic treatment due to detection of PeV-A. Coinfections were more common with PeV-A non-type 3 infections.

It is unclear if the presence of coinfections or co-detections has any impact on the PeV and/or bacterial infection. This should be further explored. The possibility of asymptomatic PeV-A carriage adds complexity to this knowledge gap.

The non-sterile site results may not be as helpful in determining true disease, but help to understand the epidemiology of certain genotypes (types 1, 5, 6). We were able to demonstrate that although these types circulate in our population, they are unlikely to cause viremia/severe disease.

Our retrospective study had limitations. We did not follow and evaluate the long-term outcomes of patients for the reported study period. Our study lasted 3 years; a longer period of observation would allow better assessment of year-to-year variation. However, by identifying a large number of infants, we confirmed the value of testing multiple samples from different body sites and provided a better understanding of the seasonality of infection.

Our study shows that PeV-A is a common infection in young infants that can be detected yearround. A picture emerges of a brief, self-limited febrile illness with fussy behavior and sometimes rash as the prominent features and laboratory findings of leukopenia and lymphopenia. The neurologic manifestations, even in infants with PCR positive specimens from CSF, were mild and apparently self-limited in this cohort. Testing specimens from multiple body compartments increases the diagnostic yield. PeV-A3 was the most common type identified. J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f 

Enterovirus and parechovirus infection in children: a brief overview

The human Parechoviruses: an overview

Enterovirus and Human Parechovirus Surveillance -United States

Comparison of epidemiology and clinical characteristics of infections by human parechovirus vs. those by enterovirus during the first month of life

Characteristics of young infants in whom human parechovirus, enterovirus or neither were detected in cerebrospinal fluid during sepsis evaluations

Dermatologic manifestations of human parechovirus type 3 infection in neonates and infants

Human parechoviruses as an important viral cause of sepsislike illness and meningitis in young children

Human parechovirus type 3 infection: An emerging infection in neonates and young infants

Strategies to improve detection and management of human parechovirus infection in young infants. The Lancet Infectious diseases

Human Parechovirus 3: The Most Common Viral Cause of Meningoencephalitis in Young Infants

Outcome of routine cerebrospinal fluid screening for enterovirus and human parechovirus infection among infants with sepsislike illness or meningitis in Cornwall, UK

Epidemiology and clinical characteristics of infants with human parechovirus or human herpes virus-6 detected in cerebrospinal fluid tested for enterovirus or herpes simplex virus

Human parechovirus 3 causing sepsis-like illness in children from midwestern United States

Cluster of human parechovirus infections as the predominant cause of sepsis in neonates and infants

Polymerase chain reaction for human parechovirus on blood samples improves detection of clinical infections in infants

Introduction of a novel parechovirus RT-PCR clinical test in a regional medical center

A novel enterovirus and parechovirus multiplex one-step real-time PCR-validation and clinical experience

Detection of all known parechoviruses by realtime PCR

A novel real-time PCR system for simultaneous detection of human viruses in clinical samples from patients with uncertain diagnoses

Human parechoviruses are frequently detected in stool of healthy Finnish children

Defining cerebrospinal fluid white blood cell count reference values in neonates and young infants

Multiple sites PCR testing for enteroviruses in young febrile infants. The Lancet Infectious diseases

Enterovirus and parechovirus meningitis in infants younger than 90 days old in the UK and Republic of Ireland: a British Paediatric Surveillance Unit study

Detection of human Parechovirus in respiratory samples in the neonatal population with fever of unknown origin

Human Parechovirus 3 in Infants: Expanding our Knowledge of Adverse Outcomes

Human parechovirus type 3 and 4 associated with severe infections in young children

Clinical characteristics of human parechoviruses 4-6 infections in young children

Enterovirus and Parechovirus Surveillance -United States

Intensive Care Admissions for Children With Enterovirus and Human Parechovirus Infections in the United Kingdom and The Republic of Ireland

Severe Parechovirus 3 Infections in Young Infants-Kansas and Missouri

Parechovirus Encephalitis and Neurodevelopmental Outcomes

High prevalence of developmental concern amongst infants at 12 months following hospitalised parechovirus infection

Acute Disseminated Encephalomyelitis After Human Parechovirus Infection

Human parechovirus infection in children in Taiwan: a retrospective, single-hospital study

The role of infections and coinfections with newly identified and emerging respiratory viruses in children

Genotyping of human parechoviruses in Iranian young children with aseptic meningitis and sepsis-like illness